SHR-8068

AssetAntibody

Monoclonal antibody targeting CD73 (NT5E) to inhibit adenosine-mediated immunosuppression.

Stage: Phase 2
Modality: Antibody
Target: CD73
Indications: 1
Trials: 151
Developers: 1

Indications

1

Locally advanced resectable rectal cancer
Phase 2RECRUITINGNCT07454720clinicaltrials.gov7 Oct 2026

Targets and what it contains2
Owner and partners1
Trials151
Evidence for its targets1
Competitors6
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 2 sources